This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (28)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Occupational and Environmental Medicine  • Alert me on articles by topic

David K. Henderson, MD

JAMA. 1999;281:931-936.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

Postexposure chemoprophylaxis is now recommended for health care workers who experience certain kinds of occupational exposures to the human immunodeficiency virus (HIV) in the workplace. Substantial information has emerged that supports but does not prove the efficacy of antiretroviral agents in preventing HIV infection after occupational exposure. This article reviews the data that have accrued in the past 8 years that bear directly on this question and describes a systematic approach to the clinical management of health care workers occupationally exposed to HIV.

The risks for occupational exposure to and infection with HIV have been apparent since the 1980s.^1-2 To address these risks, the US Public Health Service has issued a series of guidelines that have been designed to limit health care workers' risks for occupational exposure to blood and body fluids.^3-6 At approximately the same time that occupational risk for HIV infection was identified, investigators . . . [Full Text of this Article]

MECHANISMS OF ACTION

SAFETY AND EFFICACY OF ANTIRETROVIRAL CHEMOPROPHYLAXIS

EFFICACY OF ANTIRETROVIRAL CHEMOPROPHYLAXIS

Animal Studies

Relevant Human Studies

CLINICAL MANAGEMENT

COMMENT

Author Affiliation: Office of the Deputy Director for Clinical Care, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Md.

RELATED ARTICLE

March 10, 1999
JAMA. 1999;281(10):959-960.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Use of Stored Serum from Uganda for Development and Evaluation of a Human Immunodeficiency Virus Type 1 Testing Algorithm Involving Multiple Rapid Immunoassays
Singer et al.
J. Clin. Microbiol. 2005;43:5312-5315.
ABSTRACT | FULL TEXT  

Performance of the OraQuick Rapid Antibody Test for Diagnosis of Human Immunodeficiency Virus Type 1 Infection in Patients with Various Levels of Exposure to Highly Active Antiretroviral Therapy
O'Connell et al.
J. Clin. Microbiol. 2003;41:2153-2155.
ABSTRACT | FULL TEXT  

Solid-Organ Transplantation in HIV-Infected Patients
Halpern et al.
NEJM 2002;347:284-287.
FULL TEXT  

Infection Control in the ICU
Eggimann and Pittet
Chest 2001;120:2059-2093.
ABSTRACT | FULL TEXT  

Post-exposure prophylaxis for human immunodeficiency virus: knowledge and experience of junior doctors
Chen et al.
Sex. Transm. Infect. 2001;77:444-445.
ABSTRACT | FULL TEXT  

Human Immunodeficiency Virus Postexposure Prophylaxis for Adolescents and Children
Merchant and Keshavarz
Pediatrics 2001;108 :e38-e38.
ABSTRACT | FULL TEXT  

Nosocomial Spread of Viral Disease
Aitken and Jeffries
Clin. Microbiol. Rev. 2001;14:528-546.
ABSTRACT | FULL TEXT  

Susceptibility of the Porcine Endogenous Retrovirus to Reverse Transcriptase and Protease Inhibitors
Qari et al.
J. Virol. 2001;75:1048-1053.
ABSTRACT | FULL TEXT  

Postexposure Prophylaxis for Occupational Exposure to HIV
Bangsberg et al.
JAMA 1999;282:1623-1624.
FULL TEXT